3531a950-9532-4b22-93bc-f7f9551bc08c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- DNA_REPAIR+0.400
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- G2M_CHECKPOINT+0.300
- FATTY_ACID_METABOLISM+0.100
- MYC_TARGETS_V1+0.100
- PANCREAS_BETA_CELLS+0.100
- SPERMATOGENESIS+0.100
- ADIPOGENESIS+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- TGF_BETA_SIGNALING-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- APOPTOSIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- COMPLEMENT-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1b572d35-f98e-4389-b234-a2591a74d7a8 | — | — | 0.905 |
| 2 | MNG563 | — | — | 0.883 |
| 3 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.883 |
| 4 | SRR8526719 | — | cohortMD1 | 0.876 |
| 5 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.870 |
| 6 | SAMN03290891 | — | — | 0.870 |
| 7 | X0c9d8dde.aec7.4a95.b86c.da554465897b | — | cohortSQ1 | 0.869 |
| 8 | SRR2780123 | — | — | 0.866 |
| 9 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.864 |
| 10 | 6dfa8fc5-ebbc-4e1d-865f-d9026eebd62d | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |